GLIOMA, MALIGNANT

This early-stage study is testing whether the drug niraparib can effectively reach brain tumors and slow their growth. It involves 42 adults with newly diagnosed glioblastoma or a specific type of recurrent brain cancer. The trial first checks if the drug gets into the tumor duri…

This early-stage study is testing the safety of a personalized cancer vaccine for adults with a newly diagnosed, aggressive brain tumor called glioblastoma. The vaccine is designed to train the patient's immune system to attack the tumor. Researchers will give the vaccine to a sm…

This early-stage trial is testing a new drug called AZD1390 in combination with standard radiation therapy for adults with aggressive brain tumors (grade 4 glioma or glioblastoma). The study first checks if the drug successfully reaches the tumor tissue. Patients whose tumors sho…

This study aims to better understand how aggressive brain tumors (gliomas) suppress a patient's immune system. Researchers will use special MRI and PET scans on 31 adult patients with confirmed malignant glioma to look for specific immune cells and iron deposits in the tumor. The…

This early study aims to understand if an experimental drug called niraparib reaches brain tumor tissue effectively. It involves 16 adults with recurrent, slow-growing brain tumors (gliomas) who are already scheduled for surgery. Researchers will measure how much of the drug gets…